Henlius advances cetuximab biosimilar toward the U.S. market

Henlius said it has received U.S. FDA investigational new drug clearance for HLX05-N, its cetuximab biosimilar candidate referencing Erbitux, according to trade coverage of the announcement and the company’s recent filings. Henlius has described HLX05-N as a biosimilar intended for colorectal cancer and head and neck squamous cell carcinoma, and its April 2026 disclosures in Hong Kong and on its website said the company planned to start an international multicenter phase 1 study after China’s NMPA cleared the program for metastatic colorectal cancer. FDA materials also suggest there still isn’t an approved cetuximab biosimilar on the U.S. market, which would make HLX05-N an early entrant in a still-open biosimilar category if development advances. (www1.hkexnews.hk)

Why it matters: For veterinary professionals, this is mostly a market signal rather than a practice-changing event. Cetuximab is a human oncology biologic, not a veterinary product, but FDA IND clearance shows Henlius is expanding its U.S. biosimilar pipeline in oncology, where manufacturing capacity, regulatory experience, and pricing pressure can influence the broader biologics landscape. FDA notes that biosimilars can expand treatment options and may lower costs, while oncology literature has long pointed to cost and adoption as the central issues shaping biosimilar uptake. (fda.gov)

What to watch: Watch for trial initiation details, first-patient-dosed announcements, and any confirmation from Henlius on study design, timing, or U.S. development partners. (www1.hkexnews.hk)